BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

...Treatment for the Reality of Depression” ). Kineta raises $5M in private round Immunotherapy company Kineta Inc....
...funding round led by Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase BioCentury Staff Kineta Inc. BerGenBio...
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

...Sante et de la Recherche Medicale (INSERM) University of Helsinki Howard Hughes Medical Institute Merck & Co. Inc. Pfizer Inc. Kineta Inc. DEAD...
BioCentury | Sep 27, 2017
Distillery Therapeutics

Infectious disease

...fever. GeoVax Labs Inc. has GEO-LM01 , a vaccine against Lassa fever, in preclinical testing. Kineta Inc....
BioCentury | Sep 8, 2017
Company News

Merck acquires cancer play Rigontec

...induces apoptosis of tumor cells while sparing normal bystanders. Kineta Immuno-Oncology LLC, a subsidiary of Kineta Inc....
...Germany Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Elizabeth S. Eaton CRS-207 Keytruda RGT100 SD-101 Aduro Biotech Inc. Dynavax Technologies Corp. Kineta Inc. Merck...
BioCentury | Sep 6, 2017
Company News

Merck acquires cancer play Rigontec

...normal bystanders (see BioCentury Innovations, July 28, 2016) . Kineta Immuno-Oncology LLC, a subsidiary of Kineta Inc....
BioCentury | Sep 6, 2017
Preclinical News

Human mAbs could treat Lassa fever

...LHF-535 , a small molecule antiviral with activity against Lassa virus and other arenaviruses from Kineta Inc....
...is also in preclinical development (see BioCentury Innovations, June 30, 2016) . Elizabeth S. Eaton GEO-LM01 LHF-535 GeoVax Labs Inc. Kineta Inc. Orgentec...
BioCentury | May 31, 2017
Distillery Therapeutics

Transplant

...the synthetic RIG-I agonist ImOI100 (RGT100) in Phase I/II testing for lymphoma and solid tumors. Kineta Inc....
BioCentury | Jun 30, 2016
Translation in Brief

Preempting Lassa

...an award of up to £5 million ($6.7 million) from the Wellcome Trust in May, Kineta Inc....
...arenaviruses as a class. Kineta has not disclosed the compound's molecular target. On April 22, Kineta...
...instead in-licensed from Siga Technologies Inc. (NASDAQ:SIGA). Iadonato said the Wellcome Trust award should allow Kineta...
BioCentury | May 18, 2015
Clinical News

Dalazatide: Phase Ib data

...dalazatide showed an improvement in Psoriasis Area and Severity Index (PASI) score at day 32. Kineta...
...analysis of blood and skin biopsies from patients in the trial are expected this quarter. Kineta...
...under a 2009 deal (see BioCentury, July 13, 2009). Airmid Inc. , Redwood City, Calif. Kineta Inc....
BioCentury | May 11, 2015
Product Development

Check your effectors

...Phase Ib data reported last week for Kineta Inc .'s dalazatide gave the first clinical evidence...
...the target lesion and looking at what is happening to it over time," he said. Kineta...
...less likely to cause immunosuppression than therapies that universally suppress T cell activity. He said Kineta...
Items per page:
1 - 10 of 30
BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

...Treatment for the Reality of Depression” ). Kineta raises $5M in private round Immunotherapy company Kineta Inc....
...funding round led by Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase BioCentury Staff Kineta Inc. BerGenBio...
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

...Sante et de la Recherche Medicale (INSERM) University of Helsinki Howard Hughes Medical Institute Merck & Co. Inc. Pfizer Inc. Kineta Inc. DEAD...
BioCentury | Sep 27, 2017
Distillery Therapeutics

Infectious disease

...fever. GeoVax Labs Inc. has GEO-LM01 , a vaccine against Lassa fever, in preclinical testing. Kineta Inc....
BioCentury | Sep 8, 2017
Company News

Merck acquires cancer play Rigontec

...induces apoptosis of tumor cells while sparing normal bystanders. Kineta Immuno-Oncology LLC, a subsidiary of Kineta Inc....
...Germany Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Elizabeth S. Eaton CRS-207 Keytruda RGT100 SD-101 Aduro Biotech Inc. Dynavax Technologies Corp. Kineta Inc. Merck...
BioCentury | Sep 6, 2017
Company News

Merck acquires cancer play Rigontec

...normal bystanders (see BioCentury Innovations, July 28, 2016) . Kineta Immuno-Oncology LLC, a subsidiary of Kineta Inc....
BioCentury | Sep 6, 2017
Preclinical News

Human mAbs could treat Lassa fever

...LHF-535 , a small molecule antiviral with activity against Lassa virus and other arenaviruses from Kineta Inc....
...is also in preclinical development (see BioCentury Innovations, June 30, 2016) . Elizabeth S. Eaton GEO-LM01 LHF-535 GeoVax Labs Inc. Kineta Inc. Orgentec...
BioCentury | May 31, 2017
Distillery Therapeutics

Transplant

...the synthetic RIG-I agonist ImOI100 (RGT100) in Phase I/II testing for lymphoma and solid tumors. Kineta Inc....
BioCentury | Jun 30, 2016
Translation in Brief

Preempting Lassa

...an award of up to £5 million ($6.7 million) from the Wellcome Trust in May, Kineta Inc....
...arenaviruses as a class. Kineta has not disclosed the compound's molecular target. On April 22, Kineta...
...instead in-licensed from Siga Technologies Inc. (NASDAQ:SIGA). Iadonato said the Wellcome Trust award should allow Kineta...
BioCentury | May 18, 2015
Clinical News

Dalazatide: Phase Ib data

...dalazatide showed an improvement in Psoriasis Area and Severity Index (PASI) score at day 32. Kineta...
...analysis of blood and skin biopsies from patients in the trial are expected this quarter. Kineta...
...under a 2009 deal (see BioCentury, July 13, 2009). Airmid Inc. , Redwood City, Calif. Kineta Inc....
BioCentury | May 11, 2015
Product Development

Check your effectors

...Phase Ib data reported last week for Kineta Inc .'s dalazatide gave the first clinical evidence...
...the target lesion and looking at what is happening to it over time," he said. Kineta...
...less likely to cause immunosuppression than therapies that universally suppress T cell activity. He said Kineta...
Items per page:
1 - 10 of 30